People · Operator

Omri Alexander Amirav-Drory

Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology

1
Companies
1
Filings
$15.8M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
ImmuneBridge Inc.BiotechnologySeries A$15.8M$20.8M2025
Operator network

Omri Alexander Amirav-Drory at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Gregory A. Bonfiglio · 2 companies · 1 sharedGregory A. Bonfig…Alicia Alexander Jackson · 1 companies · 1 sharedAlicia Alexander …Alicia Kim Jackson · 1 companies · 1 sharedAlicia Kim JacksonCheryl Kim Zimberlin · 1 companies · 1 sharedCheryl Kim Zimber…Dylan Alexander Morris · 1 companies · 1 sharedDylan Alexander M…Dylan Kim Morris · 1 companies · 1 sharedDylan Kim MorrisMary Kim Warren · 1 companies · 1 sharedMary Kim WarrenNadiya Alexander Ishnazarova · 1 companies · 1 sharedNadiya Alexander …Peretz Partensky · 1 companies · 1 sharedPeretz PartenskyStuart Alexander Jacobson · 1 companies · 1 sharedStuart Alexander …Thomas Alexander Farrell · 1 companies · 1 sharedThomas Alexander …ImmuneBridge Inc. · $15.8M raisedImmuneBridge Inc.Omri Alexander Amirav-DroryOA
Omri Alexander Amirav-Drory Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Omri Alexander Amirav-Drory on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Gregory A. Bonfiglio12
Dylan Alexander Morris11
Nadiya Alexander Ishnazarova11
Alicia Alexander Jackson11
Stuart Alexander Jacobson11
Thomas Alexander Farrell11
Alicia Kim Jackson11
Cheryl Kim Zimberlin11
Peretz Partensky11
Dylan Kim Morris11
Mary Kim Warren11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.